EGFR and neoplasm: Different studies have demonstrated that in ctDNA EGFR mutant patients treated with EGFR TKIs, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) are similar to that in patients with EGFR mutations detected in tumor tissue [49,50,51,52].